JP2023538906A5 - - Google Patents
Info
- Publication number
- JP2023538906A5 JP2023538906A5 JP2023511946A JP2023511946A JP2023538906A5 JP 2023538906 A5 JP2023538906 A5 JP 2023538906A5 JP 2023511946 A JP2023511946 A JP 2023511946A JP 2023511946 A JP2023511946 A JP 2023511946A JP 2023538906 A5 JP2023538906 A5 JP 2023538906A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- nectin
- patient
- tumor tissue
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025185568A JP2026027329A (ja) | 2020-08-17 | 2025-11-04 | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066434P | 2020-08-17 | 2020-08-17 | |
| US63/066,434 | 2020-08-17 | ||
| US202163134202P | 2021-01-06 | 2021-01-06 | |
| US63/134,202 | 2021-01-06 | ||
| US202163171654P | 2021-04-07 | 2021-04-07 | |
| US63/171,654 | 2021-04-07 | ||
| PCT/EP2021/072866 WO2022038158A1 (en) | 2020-08-17 | 2021-08-17 | Bicycle conjugates specific for nectin-4 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185568A Division JP2026027329A (ja) | 2020-08-17 | 2025-11-04 | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538906A JP2023538906A (ja) | 2023-09-12 |
| JP2023538906A5 true JP2023538906A5 (enExample) | 2024-08-13 |
Family
ID=77666485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511946A Pending JP2023538906A (ja) | 2020-08-17 | 2021-08-17 | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
| JP2025185568A Pending JP2026027329A (ja) | 2020-08-17 | 2025-11-04 | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185568A Pending JP2026027329A (ja) | 2020-08-17 | 2025-11-04 | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240240255A1 (enExample) |
| EP (2) | EP4196792B1 (enExample) |
| JP (2) | JP2023538906A (enExample) |
| KR (1) | KR20230074721A (enExample) |
| CN (1) | CN116234931B (enExample) |
| AU (1) | AU2021327130A1 (enExample) |
| CA (1) | CA3186504A1 (enExample) |
| DK (1) | DK4196792T3 (enExample) |
| ES (1) | ES3075789T3 (enExample) |
| FI (1) | FI4196792T3 (enExample) |
| IL (1) | IL300450A (enExample) |
| MX (1) | MX2023001588A (enExample) |
| PT (1) | PT4196792T (enExample) |
| WO (1) | WO2022038158A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| US20250186539A2 (en) * | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| CN115804161A (zh) | 2021-05-11 | 2023-03-14 | 中兴通讯股份有限公司 | 用于多trp操作中的上行链路传输的tpc命令值的增强指示的方法和系统 |
| CN116768978A (zh) * | 2022-03-11 | 2023-09-19 | 上海智肽生物科技有限公司 | Nectin-4靶向肽化合物及其药物偶联物 |
| EP4719481A1 (en) * | 2023-06-01 | 2026-04-08 | BicycleTx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| WO2024248859A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| CN117069806B (zh) * | 2023-08-17 | 2024-10-11 | 湖南中晟全肽生物科技股份有限公司 | 一种肿瘤细胞靶向多肽及应用 |
| WO2025125652A1 (en) * | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Combination therapy for use in treating cancer |
| WO2025125809A1 (en) * | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| WO2025125648A1 (en) * | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Bicyclic peptide complex for use in treating cancer |
| WO2025248261A1 (en) | 2024-05-31 | 2025-12-04 | Bicycletx Limited | Method for identifying patients |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| BR0007545B1 (pt) | 1999-01-18 | 2010-04-06 | material resistente à penetração, e, artigo. | |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US7998695B2 (en) * | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| JP6074574B2 (ja) | 2008-02-05 | 2017-02-08 | バイシクル セラピューティクス リミテッド | 方法及び組成物 |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US20130122499A1 (en) * | 2011-11-14 | 2013-05-16 | Viomics, Inc. | System and method of detecting local copy number variation in dna samples |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2015112534A2 (en) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| US11274160B2 (en) * | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| CN107217308A (zh) * | 2017-06-21 | 2017-09-29 | 北京贝瑞和康生物技术股份有限公司 | 一种用于检测染色体拷贝数变异的测序文库构建方法和试剂盒 |
| CA3095582A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
-
2021
- 2021-08-17 WO PCT/EP2021/072866 patent/WO2022038158A1/en not_active Ceased
- 2021-08-17 PT PT217664200T patent/PT4196792T/pt unknown
- 2021-08-17 EP EP21766420.0A patent/EP4196792B1/en active Active
- 2021-08-17 JP JP2023511946A patent/JP2023538906A/ja active Pending
- 2021-08-17 ES ES21766420T patent/ES3075789T3/es active Active
- 2021-08-17 IL IL300450A patent/IL300450A/en unknown
- 2021-08-17 KR KR1020237008781A patent/KR20230074721A/ko active Pending
- 2021-08-17 FI FIEP21766420.0T patent/FI4196792T3/fi active
- 2021-08-17 CA CA3186504A patent/CA3186504A1/en active Pending
- 2021-08-17 AU AU2021327130A patent/AU2021327130A1/en active Pending
- 2021-08-17 CN CN202180063232.XA patent/CN116234931B/zh active Active
- 2021-08-17 MX MX2023001588A patent/MX2023001588A/es unknown
- 2021-08-17 DK DK21766420.0T patent/DK4196792T3/da active
- 2021-08-17 EP EP26180678.0A patent/EP4779311A2/en active Pending
- 2021-08-17 US US18/021,748 patent/US20240240255A1/en active Pending
-
2025
- 2025-11-04 JP JP2025185568A patent/JP2026027329A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529214A5 (enExample) | ||
| Viloria-Petit et al. | Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies | |
| Hattinger et al. | An update on emerging drugs in osteosarcoma: towards tailored therapies? | |
| Sawada et al. | Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. | |
| Muñoz et al. | The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists | |
| Choi et al. | Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. | |
| Miller et al. | MEK1/2 inhibitors in the treatment of gynecologic malignancies | |
| CN110769820A (zh) | 作为ros1激酶抑制剂的大环化合物 | |
| ES2204886T3 (es) | Receptores de factor de crecimiento fibroblastico. | |
| JP2018194556A (ja) | 併用抗がん剤の感受性判定マーカー | |
| Chou et al. | Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study | |
| SG175208A1 (en) | Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors | |
| Fukuda et al. | Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer | |
| BR112020026382A2 (pt) | combinações de poziotinibe com um anticorpo anti-her1, her2 ou her4 e métodos de uso das mesmas | |
| WO2013024158A1 (en) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection | |
| Siena et al. | Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001) | |
| CN109709335B (zh) | 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用 | |
| ES3019008T3 (en) | Predicting peptide receptor radiotherapy using a gene expression assay | |
| AU2024356380A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors | |
| Daneshmand et al. | PROOF 302: a randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations | |
| CN115175678B (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| Vanhoefer | Molecular mechanisms and targeting of colorectal cancer | |
| Raza et al. | Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck | |
| Knoerzer et al. | Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models | |
| Choi et al. | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer |